In 2023, genetic arterial-specific deletion of ALK1 and monoclonal antibody blockade of ALK1 were shown to block LDL transcytosis and reduce atherosclerosis in vitro and in LDL receptor knockout mice fed a high-fat diet [124]. The gene discussed is LDLR; the disease is atherosclerosis.